This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Neuroblastoma - Pipeline Insight, 2019 with Analysis by Developmental Stage, Associated Indications, Route of Administration and Molecule Type - ResearchAndMarkets.com

February 27, 2019

DUBLIN--(BUSINESS WIRE)--Feb 27, 2019--The “Neuroblastoma - Pipeline Insight, 2019” drug pipelines report has been added to ResearchAndMarkets.com’s offering.

This report offers comprehensive insight of the pipeline (under development) therapeutics scenario and growth prospects across Neuroblastoma development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the Report

  • The report provides a snapshot of the pipeline development for Neuroblastoma
  • The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for Neuroblastoma
  • The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Neuroblastoma
  • The report also covers the dormant and discontinued pipeline projects related to Neuroblastoma

Reasons to Buy

  • Establish comprehensive understanding of the pipeline activity across Neuroblastoma to formulate effective R&D strategies
  • Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
  • Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Neuroblastoma therapeutics
  • Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

Companies Mentioned

  • Ability Pharmaceuticals S.L.
  • Actuate Therapeutics Inc.
  • Advanced Accelerator Applications S.A.
  • Alissa Pharma
  • Ampio Pharmaceuticals Inc.
  • APAvadis Biotechnologies S.r.l.
  • APEIRON Biologics AG
  • AstraZeneca PLC
  • Bayer AG
  • Bellicum Pharmaceuticals Inc.
  • Bexion Pharmaceuticals LLC
  • BioLineRx Ltd.
  • Biotec Pharmacon ASA
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cancer Prevention Pharmaceuticals Inc.
  • Cebiotex S.L.

Topics Covered

1. Report Introduction

2. Neuroblastoma Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Neuroblastoma

4. Comparative Analysis

5. Products in Clinical Stage

  • Product Description
  • Research and Development
  • Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment

  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

8. Inactive Products

  • Product Description
  • Research and Development
  • Product Development Activities

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/l2zz98/neuroblastoma?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190227005863/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs,Brain Cancer Drugs



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/27/2019 02:51 PM/DISC: 02/27/2019 02:52 PM